for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Takeda Pharmaceutical Co Ltd

4502.T

Latest Trade

4,191.00JPY

Change

28.00(+0.67%)

Volume

12,462,400

Today's Range

4,127.00

 - 

4,194.00

52 Week Range

2,894.50

 - 

4,562.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
4,163.00
Open
4,140.00
Volume
12,462,400
3M AVG Volume
162.50
Today's High
4,194.00
Today's Low
4,127.00
52 Week High
4,562.00
52 Week Low
2,894.50
Shares Out (MIL)
1,557.77
Market Cap (MIL)
6,606,583.00
Forward P/E
49.17
Dividend (Yield %)
4.29

Next Event

Takeda Pharmaceutical Co Ltd at Jefferies Healthcare Conference (Virtual)

Latest Developments

More

Takeda Announces Compelling Data From Phase 2 Trial Of Pevonedistat Plus Azacitidine In Patients With Higher-Risk MDS

U.S. FDA Approves Takeda's Alunbrig As A First-Line Treatment For Patients With Rare Form Of Lung Cancer

Phathom Pharma On May 5, Entered Into A Commercial Supply Agreement With Takeda Pharmaceutical Company Limited

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Takeda Pharmaceutical Co Ltd

Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.

Industry

Major Drugs

Contact Info

4F, 2-1-1, Nihombashihon-cho

CHUO-KU, TKY

103-8668

Japan

+81.3.32782111

https://www.takeda.com/

Executive Leadership

Masahiro Sakane

Independent Chairman of the Executive Board

Christophe Weber

President, Chief Executive Officer, Representative Director

Constantine Saroukos

Chief Financial Officer, Director

Masato Iwasaki

President of Japan Pharma Business Unit, President of Subsidiary, Director

Andrew S. Plump

President of Research & Development, Director

Key Stats

1.85 mean rating - 13 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2018

1.8K

2019

2.1K

2020

3.3K

2021(E)

3.3K
EPS (JPY)

2018

239.350

2019

113.500

2020

28.410

2021(E)

84.665
Price To Earnings (TTM)
148.06
Price To Sales (TTM)
2.01
Price To Book (MRQ)
1.38
Price To Cash Flow (TTM)
10.52
Total Debt To Equity (MRQ)
107.83
LT Debt To Equity (MRQ)
95.41
Return on Investment (TTM)
0.40
Return on Equity (TTM)
0.33

Latest News

Latest News

BRIEF-Takeda Announces Compelling Data From Phase 2 Trial Of Pevonedistat Plus Azacitidine In Patients With Higher-Risk MDS

* TAKEDA ANNOUNCES COMPELLING DATA FROM THE PHASE 2 TRIAL OF PEVONEDISTAT PLUS AZACITIDINE IN PATIENTS WITH HIGHER-RISK MDS

Takeda gets EU green light to keep bowel drug after Shire buy

Japan's Takeda Pharmaceutical Co Ltd will be allowed to keep a drug used to treat bowel disease because changes in the market have removed the need to sell it to allay EU antitrust concerns over last year's acquisition of Shire plc.

EU regulators allow Takeda to buy Shire without selling asset

Japan's Takeda Pharmaceutical Co Ltd will not be required to sell a biologic drug, a concession made to address EU antitrust concerns over its 2018 bid to buy Shire, because market condition have changed, EU regulators said on Thursday.

BRIEF-U.S. FDA Approves Takeda's Alunbrig As A First-Line Treatment For Patients With Rare Form Of Lung Cancer

* U.S. FDA APPROVES TAKEDA’S ALUNBRIG® (BRIGATINIB) AS A FIRST-LINE TREATMENT OPTION FOR PATIENTS DIAGNOSED WITH RARE AND SERIOUS FORM OF LUNG CANCER

Takeda says coronavirus treatment trial using recovered patients' blood could start in July

Takeda Pharmaceutical Co Ltd could start a clinical trial as early as July for a potential treatment of COVID-19 that is based on antibodies from recovered patients' blood, company executives said on Wednesday.

Takeda Pharma logs surprise profit, updates on COVID-19 therapy

Takeda Pharmaceutical Co booked a surprise operating profit and forecast that income would triple this business year as hefty acquisition costs related to last year's $59 billion Shire takeover recede.

Takeda Pharma posts full-year operating profit amid Shire consolidation

Takeda Pharmaceutical Co Ltd said on Wednesday it had posted a full-year operating profit, surprising analysts who had expected it to make a loss on the hefty costs that came with last year's $59 billion takeover of Shire Plc.

BRIEF-Phathom Pharma On May 5, Entered Into A Commercial Supply Agreement With Takeda Pharmaceutical Company Limited

* PHATHOM PHARMACEUTICALS INC - ON MAY 5, ENTERED INTO A COMMERCIAL SUPPLY AGREEMENT WITH TAKEDA PHARMACEUTICAL COMPANY LIMITED

BRIEF-Takeda Announces U.S. FDA Breakthrough Therapy Designation For Mobocertinib (TAK-788)

* TAKEDA ANNOUNCES U.S. FDA BREAKTHROUGH THERAPY DESIGNATION FOR MOBOCERTINIB (TAK-788) FOR THE TREATMENT OF NSCLC PATIENTS WITH EGFR EXON 20 INSERTION MUTATIONS

Japan's Takeda sells $670 million of Europe OTC assets to pare debt

Japan's Takeda Pharmaceutical Co Ltd <4502.T> said it would sell up to $670 million of over-the-counter drug operations in Europe to pare debt ahead of its full-year earnings announcement.

Japanese drug firm Takeda to sell some assets in Europe to Orifarm

Takeda Pharmaceutical Co <4502.T> said it would sell selected over-the-counter (OTC) and prescription pharmaceutical products that are sold in Europe to Orifarm Group.

Japanese drug firm Takeda to sell some assets in Europe to Orifarm

Takeda Pharmaceutical Co said it would sell selected over-the-counter (OTC) and prescription pharmaceutical products that are sold in Europe to Orifarm Group.

Japan's Takeda plans to sell consumer health unit for around $3.7 bln - Nikkei

Japan's Takeda Pharmaceutical Co Ltd plans to sell its consumer health unit for around 400 billion yen ($3.72 billion), Nikkei Business reported.

BRIEF-Prothera Biologics And Takeda Enter Global Licensing Agreement To Develop Novel Plasma-Derived Therapy Based On Inter-Alpha Inhibitor Proteins

* PROTHERA BIOLOGICS AND TAKEDA ENTER GLOBAL LICENSING AGREEMENT TO DEVELOP NOVEL PLASMA-DERIVED THERAPY BASED ON INTER-ALPHA INHIBITOR PROTEINS (IAIP)

Johnson & Johnson abandons deal for Takeda's TachoSil surgical patch

Johnson & Johnson said on Friday it abandoned plans to buy Takeda Pharmaceutical’s surgical patch product TachoSil, citing regulatory issues.

Johnson & Johnson abandons deal for Takeda's TachoSil surgical patch, FTC says

Johnson & Johnson has abandoned plans to buy Takeda Pharmaceutical’s surgical patch product TachoSil, the Federal Trade Commission said on Friday.

BRIEF-Takeda Says European Commission Approved Alunbrig As A First-Line Treatment For ALK+ NSCLC

* EUROPEAN COMMISSION APPROVES TAKEDA’S ALUNBRIG® (BRIGATINIB) AS A FIRST-LINE TREATMENT FOR ALK+ NSCLC

BRIEF-Global Plasma Leaders Collaborate To Accelerate Development Of Potential Covid-19 Hyperimmune Therapy

* GLOBAL PLASMA LEADERS COLLABORATE TO ACCELERATE DEVELOPMENT OF POTENTIAL COVID-19 HYPERIMMUNE THERAPY

BRIEF-Evotec Enters Gene Therapy Alliance with Takeda, No Financial Details Given

* EVOTEC AND TAKEDA ENTER INTO MULTI-YEAR GENE THERAPY RESEARCH ALLIANCE

BRIEF-Takeda Adopts Executive Compensation Recoupment Policy

* ADOPTS EXECUTIVE COMPENSATION RECOUPMENT POLICY Source text: https://bit.ly/2QYOq9E Further company coverage: (Reporting By Rocky Swift)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up